| Literature DB >> 34345291 |
Zhi-Min Deng1, Fang-Fang Dai1, Meng-Qin Yuan1, Dong-Yong Yang1, Ya-Jing Zheng1, Yan-Xiang Cheng1.
Abstract
Pelvic organ prolapse (POP) is a common gynecological benign disease occurring in middle-aged and elderly females. Its incidence increases every year. To date, the majority of studies investigating its etiology have not evaluated the underlying molecular mechanisms, which has caused substantial difficulties in the prevention, treatment and prognosis of POP. In the present narrative review, recent research studies concerning the molecular mechanisms of POP were systematically reviewed and the advances were summarized. The association between the incidence of POP and the reduction of the extracellular matrix, activation of oxidative stress, genetic susceptibility, denervation of the pelvic floor and reduction of estrogen infiltration were explored. POP is mainly associated with damage of pelvic floor muscles and connective tissue, which are directly caused by pregnancy and vaginal delivery. The majority of the molecular and genetic mutations associated with POP involve specific components of connective tissue synthesis and degradation. It is likely that macroscopic parameters, such as anatomy, lifestyle and reproductive factors, interact with microscopic parameters, such as physiology and genetics in the female pelvic floor, leading to POP. Additional research studies investigating the molecular mechanisms of POP should be performed, since they may aid public health strategies. In the present narrative review, a summary of these molecular mechanisms underlying the development of POP is provided. This included the relevant proteins and genes involved. On this basis, countermeasures were proposed. Copyright: © Deng et al.Entities:
Keywords: extracellular matrix; genetic polymorphism; molecular mechanisms; pelvic floor dysfunction
Year: 2021 PMID: 34345291 PMCID: PMC8311251 DOI: 10.3892/etm.2021.10442
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Molecular mechanisms of pelvic organ prolapse.
| Category | Factors | (Refs.) |
|---|---|---|
| Reduction of ECM | ||
| Reduced anabolism | TGF-β1 | ( |
| HOXA11 | ( | |
| FBLN5 | ( | |
| LOXL1 | ( | |
| Increased catabolism | MMPs/TIMPs, elastases | ( |
| Activation of oxidative stress | NA[ | ( |
| Genetic susceptibility | NA | Table II[ |
| Reduction of neurotransmitters | VIP | ( |
| NPY | ( | |
| Reduction of estrogen infiltration | NA | ( |
aFor rows containing NA, there is no precise factor available for that molecular mechanism;
bDetails are presented in Table II. ECM, extracellular matrix; TGF-β1, transforming growth factor-β1; HOXA11, homeobox A11; FBLN5, fibulin-5; LOXL1, lysyl oxidases-like protein 1; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitors of MMP; NPY, neuropeptide; VIP, vasoactive intestinal peptide.
Figure 1Overview diagram of the article. (A) Pie chart of the five core factors of POP. (B) Specific molecular mechanisms involved in the reduction of ECM. POP, pelvic organ prolapse; ECM, extracellular matrix; TGF-β1, transforming growth factor-β1; HOXA11, homeobox A11; FBLN5, fibulin-5; LOXL1, lysyl oxidases-like protein 1; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitors of MMP; NPY, neuropeptide; VIP, vasoactive intestinal peptide.
Susceptibility genes of POP.
| Genetic entity | Proven susceptibility[ | (Refs.) |
|---|---|---|
| COL3A1 rs1800255 | Yes | ( |
| No | ( | |
| COL1A1 rs1800012 | Yes | ( |
| No | ( | |
| LAMC1 rs10911193 | No | ( |
| ESR1 rs2228480 | Yes | ( |
| No | ( | |
| PGR rs484389 | Yes | ( |
| MMP1 | Yes | ( |
| No | ( | |
| HOXA11 | No | ( |
| LOXL1 | Yes | ( |
| FBLN5 | Yes | ( |
| No | ( | |
| Chromosomes 9q21/10q24-26/17q25 | Yes | ( |
aYes/no refers to whether this gene has been proven to be a susceptibility gene for POP; ‘Yes’ means that it is a susceptibility gene for POP, while ‘no’ means that there is insufficient evidence to prove that it is a susceptibility gene for POP. POP, pelvic organ prolapse; COL1A1, collagen type I α 1; COL3A1, collagen type III α 1; ESR1, estrogen receptor α; FBLN5, fibulin-5; LAMC1, laminin γ-1; MMP1, matrix metalloproteinases 1; PGR, progesterone receptor; LOXL1, lysyl oxidases-like protein 1; HOXA11, homeobox A11.